Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Administration of Neomycin Resistance Gene Marked EBV Specific Cytotoxic T-Lymphocytes to Patients With Relapsed EBV-Positive Lymphoma

NCT00058617 is registered in ClinicalTrials.gov with Baylor College of Medicine as lead sponsor.

NCT NCT00058617
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00058617 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Administration of Neomycin Resistance Gene Marked EBV Specific Cytotoxic T-Lymphocytes to Patients With Relapsed EBV-Positive Lymphoma
Lead sponsor
Baylor College of Medicine
Phase
Phase 1
Overall status
Completed
Start date
January 31, 1996
Completion date
July 31, 2014
Enrollment
13 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

ebv positive plasma cell neoplasm, epstein-barr virus-related hodgkin lymphoma, epstein-barr virus-related non-hodgkin lymphoma